Arcus Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

December 31, 2025 and 2024

(In millions, except per share amounts)

	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$222	$150
Marketable securities	759	828
Receivable from collaboration partners ($— and $6 from a related party)	11	20
Prepaid expenses and other current assets	15	18
Total current assets	1,007	1,016
Long-term marketable securities	29	14
Property and equipment, net	40	47
Other noncurrent assets	63	73
Total assets	$1,139	$1,150
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable ($24 and $— to a related party)	$42	$18
Deferred revenue ($35 and $85 to a related party)	35	85
Other current liabilities	154	123
Total current liabilities	231	226
Deferred revenue, noncurrent ($43 and $234 to a related party)	43	234
Long-term debt	99	48
Other noncurrent liabilities	135	157
Commitments (Note 17)
Stockholders’ equity:
Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 125.3 shares in 2025 and 92.2 shares in 2024 issued and outstanding	2,116	1,617
Accumulated deficit	(1,485)	(1,132)
Total stockholders’ equity	631	485
Total liabilities and stockholders’ equity	$1,139	$1,150

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.